Zicronapine

Summary

Zicronapine (CHEMBL3039528) is a phase-3 clinical-stage small molecule; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 354.9 Da · C22H27ClN2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3039528
Name	Zicronapine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11465618
Molecular formula	C22H27ClN2
Molecular weight	354.9
InChIKey	BYPMJBXPNZMNQD-PZJWPPBQSA-N

SMILES: CC1(CN(CCN1C)[C@@H]2C[C@H](C3=C2C=C(C=C3)Cl)C4=CC=CC=C4)C

IUPAC name: 4-[(1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine

Also known as: Zicronapina, Zicronapine, ZICRONAPINE

Parent form; salt/anhydrous children: CHEMBL3039534, CHEMBL5191141, CHEMBL5191777

Patent coverage: 107 distinct patent families (278 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 197 (71%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: D(1A) dopamine receptor, D(2) dopamine receptor.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD1	9.89	Ki	0.13	nM	CHEMBL_ACT_22411773
DRD2	7.55	Ki	28	nM	CHEMBL_ACT_22411748

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01295372	PHASE3	COMPLETED	Safety and Efficacy of Zicronapine in Patients With Schizophrenia
NCT00768326	PHASE2	COMPLETED	Efficacy of Lu 31-130 in Patients With Schizophrenia
NCT00770744	PHASE2	COMPLETED	Efficacy of Lu 31-130 in Patients With Schizophrenia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).